Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.

Item
http://www.wikidata.org/entity/Q34732945
Status of PI3K/Akt/mTOR pathway inhibitors in lymphomaAn endocytosis pathway initiated through neuropilin-1 and regulated by nutrient availabilityBrentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussionCombination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.Clinical response to everolimus in a patient with Hodgkin's lymphoma harboring a TSC2 mutationTime now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.mTOR inhibitors in urinary bladder cancer.Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.m-TOR inhibitors and their potential role in haematological malignancies.Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an orally administered phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor: a phase 1 expansion cohort in patients with relapsed or refractory ly
P2860

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.

Item
http://www.wikidata.org/entity/Q34732945
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@ast
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@en
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@nl
type
label
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@ast
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@en
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@nl
prefLabel
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@ast
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@en
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Characteristic mTOR activity i ...... y, in vitro and in vivo study.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P577
P5875
P6179
P698
P932